Deadline looms for Chinese biotech contracts

A bill working its way through Congress could enforce a deadline for U.S. companies to cut ties with several Chinese biotech firms.

The Biosecure Act was approved by the House Committee on Oversight and Accountability earlier this month and is expected to cause major upheaval in the U.S. biotech industry if it’s ultimately passed by Congress and signed into law.